Neuromyelitis optica spectrum disorder overview
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder overview On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder overview |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
|
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system (CNS), mainly affecting the optic nerves, spinal cord, and brainstem. Most patients have immunoglobulin G (IgG) antibodies against aquaporin-4 (AQP4), an astrocyte water-channel protein; these antibodies are termed AQP4-IgG.[1] Attacks can cause lasting visual or neurological disability. Management combines urgent attack treatment, prevention of further attacks, and care for residual impairments.[2]
Historical Perspective
Neuromyelitis optica spectrum disorder became more clearly distinguishable from multiple sclerosis (MS) after discovery of a disease-associated serum antibody in 2004 and identification of AQP4 as its target in 2005. The 2015 International Panel for Neuromyelitis Optica Diagnosis (IPND) criteria recognized a broader clinical spectrum than combined optic neuritis and myelitis.[3]
Classification
Neuromyelitis optica spectrum disorder is classified as disease with AQP4-IgG or disease without AQP4-IgG/with unknown antibody status; the latter requires stricter diagnostic evidence.[3] Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct disorder when its diagnostic criteria are fulfilled.[4]
Pathophysiology
Neuromyelitis optica spectrum disorder associated with AQP4-IgG primarily injures astrocytes. Antibody binding promotes complement activation and inflammation, with secondary demyelination and neuronal injury.[1]
Causes
Neuromyelitis optica spectrum disorder is immune mediated. AQP4-IgG is pathogenic in antibody-positive disease, while the mechanisms of antibody-negative presentations remain less well understood.[1]
Differentiating Neuromyelitis Optica Spectrum Disorder from Other Conditions
Neuromyelitis optica spectrum disorder must be differentiated from MS, MOGAD, neurosarcoidosis, infections, and vascular or neoplastic spinal cord disorders.[5] MOGAD can resemble NMOSD clinically, but has separate antibody-based diagnostic criteria.[4]
Epidemiology and Demographics
Neuromyelitis optica spectrum disorder occurs worldwide, usually begins in adulthood, and strongly predominates in women when AQP4-IgG-positive. Children and older adults can also be affected.[5]
Risk Factors
Neuromyelitis optica spectrum disorder frequently coexists with autoimmune conditions, including systemic lupus erythematosus and Sjögren's syndrome, suggesting shared autoimmune susceptibility. These associations do not establish that another autoimmune disease caused NMOSD.[5]
Screening
Neuromyelitis optica spectrum disorder antibody testing is directed by compatible clinical or imaging findings. Broad, unselected AQP4-IgG screening in otherwise typical MS is discouraged because false-positive results can lead to misdiagnosis.[5]
Natural History, Complications and Prognosis
Neuromyelitis optica spectrum disorder can cause severe visual loss, paralysis, neuropathic pain, and bowel or bladder dysfunction. Prompt attack treatment and effective relapse prevention improve outcomes.[2] AQP4-IgG-positive disease usually relapses, and disability accumulates mainly through incomplete attack recovery; gradual progression independent of attacks is uncommon.[3]
Diagnosis
Neuromyelitis optica spectrum disorder diagnosis integrates characteristic clinical syndromes, antibody testing, magnetic resonance imaging (MRI), and exclusion of alternative diagnoses. Published 2026 consensus recommendations continue to endorse the 2015 IPND criteria.[6] AQP4-IgG-positive diagnosis requires at least one core clinical characteristic and exclusion of a better explanation. Negative or unknown antibody status requires additional clinical and MRI criteria.[3]
Diagnostic Study of Choice
Neuromyelitis optica spectrum disorder has no single test that independently diagnoses every case. Serum AQP4-IgG testing using a validated cell-based assay, interpreted alongside clinical and MRI findings, is central to evaluation.[6]
History and Symptoms
Neuromyelitis optica spectrum disorder commonly presents with optic neuritis, causing visual loss, or acute myelitis, causing weakness, sensory symptoms, pain, and sphincter dysfunction. Area postrema syndrome causes otherwise unexplained persistent nausea, vomiting, or hiccups.[7] Other recognized presentations include acute brainstem, diencephalic, and cerebral syndromes.[3]
Physical Examination
Neuromyelitis optica spectrum disorder examination findings depend on lesion location. Assessment should document visual function in both eyes, pupillary responses, strength, reflexes, sensation, and bladder or bowel involvement.[5]
Laboratory Findings
Neuromyelitis optica spectrum disorder evaluation prioritizes serum AQP4-IgG. Testing for myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) helps identify MOGAD in compatible antibody-negative presentations. Results require clinical interpretation; a negative AQP4-IgG result alone does not exclude NMOSD.[6]
Magnetic Resonance Imaging
Neuromyelitis optica spectrum disorder may show extensive optic nerve or chiasmal lesions, spinal cord lesions spanning at least three contiguous vertebral segments, and characteristic brainstem or periependymal lesions. Short cord lesions or a normal brain MRI do not exclude the diagnosis.[3] MRI also supports attack assessment, monitoring, and evaluation of post-attack recovery.[8]
Other Imaging Findings
Neuromyelitis optica spectrum disorder assessment may include optical coherence tomography (OCT) to document retinal neuroaxonal loss. OCT is supportive and does not independently establish NMOSD.[5]
Other Diagnostic Studies
Neuromyelitis optica spectrum disorder assessment commonly includes lumbar puncture with cerebrospinal fluid (CSF) analysis to investigate inflammation and alternative diagnoses. Visual evoked potentials may provide additional evidence of optic pathway injury.[5]
Treatment
Neuromyelitis optica spectrum disorder treatment aims to limit acute attack damage, prevent further attacks, and manage lasting symptoms and disability.[2]
Medical Therapy
Neuromyelitis optica spectrum disorder attacks require prompt high-dose intravenous methylprednisolone, with early plasma exchange for severe or insufficiently responsive attacks. Preventive options for AQP4-IgG-positive disease include eculizumab, ravulizumab, inebilizumab, satralizumab, and rituximab. Azathioprine or mycophenolate mofetil remain alternatives when biologics are inaccessible. Selection depends on clinical circumstances and local approval.[6] Treatment of AQP4-IgG-negative disease is individualized because evidence is limited.[1]
Interventions
Neuromyelitis optica spectrum disorder attacks may require early therapeutic plasma exchange or, where available, immunoadsorption, particularly with severe deficits or inadequate response to corticosteroids. Treatment timing is important for neurological recovery.[1]
Surgery
Neuromyelitis optica spectrum disorder has no established surgery that treats its underlying autoimmune process. Selected procedures, such as intrathecal baclofen pump implantation, may help manage severe refractory spasticity.[9]
Primary Prevention
Neuromyelitis optica spectrum disorder has no established intervention or vaccine that prevents the first onset of disease.[10]
Secondary Prevention
Neuromyelitis optica spectrum disorder relapse prevention includes long-term immunotherapy, offered after the first attack in AQP4-IgG-positive disease. Treatment safety, adherence, and suspected breakthrough attacks require ongoing specialist review.[1]
Symptomatic Therapy and Rehabilitation
Neuromyelitis optica spectrum disorder care also addresses neuropathic pain, spasticity, painful tonic spasms, visual disability, and bowel or bladder dysfunction. Rehabilitation and symptom-directed treatment support function and quality of life.[9] Multidisciplinary follow-up, patient education, and psychological support should reflect individual needs.[7]
Special Populations
Neuromyelitis optica spectrum disorder during pregnancy requires coordinated neurological and obstetric care because attack risk increases postpartum.[7] Pediatric treatment and reproductive planning require individualized specialist decisions; teratogenic medicines, including mycophenolate mofetil, require planned replacement before conception.[6]
Cost-Effectiveness of Therapy
Neuromyelitis optica spectrum disorder economic assessment must consider medication costs, relapses, and disability. A 2025 Korean cohort associated rituximab with lower relapse risk but higher overall medical expenditure than oral immunosuppressants. Its observational findings do not establish a universally preferred economic option.[11]
Future or Investigational Therapies
Neuromyelitis optica spectrum disorder research includes chimeric antigen receptor T-cell (CAR-T) therapy. A small phase 1 study of a B-cell maturation antigen (BCMA)-directed product provided preliminary findings, but controlled studies and longer follow-up are needed to establish safety, efficacy, and durability.[12]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Kümpfel T, Giglhuber K, Aktas O, et al. (2024). "Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management". Journal of Neurology. 271 (1): 141–176. doi:10.1007/s00415-023-11910-z.
- ↑ 2.0 2.1 2.2 dos Apóstolos-Pereira SL, Damasceno A, Piccolo AC, et al. (2025). "2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children". Arquivos de Neuro-Psiquiatria. 83 (11). doi:10.1055/s-0045-1812471.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Wingerchuk DM, Banwell B, Bennett JL, et al. (2015). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology. 85 (2): 177–189. doi:10.1212/WNL.0000000000001729.
- ↑ 4.0 4.1 Banwell B, Bennett JL, Marignier R, et al. (2023). "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria". The Lancet Neurology. 22 (3): 268–282. doi:10.1016/S1474-4422(22)00431-8.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Jarius S, Aktas O, Ayzenberg I, et al. (2023). "Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis". Journal of Neurology. 270 (7): 3341–3368. doi:10.1007/s00415-023-11634-0.
- ↑ 6.0 6.1 6.2 6.3 6.4 Yamout B, Gouider R, Al-Roughani R, et al. (2026). "Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines". CNS Drugs. 40 (3): 283–303. doi:10.1007/s40263-025-01260-x.
- ↑ 7.0 7.1 7.2 Giorgi L, Marignier R, Pique J, et al. (2026-07-21). "French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder". Revue Neurologique. doi:10.1016/j.neurol.2026.06.004.
- ↑ Cortese R, Hacohen Y, Arrambide G, et al. (2026-09-28). "Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations". Nature Reviews Neurology. doi:10.1038/s41582-026-01271-2.
- ↑ 9.0 9.1 Abboud H, Salazar-Camelo A, George N, et al. (2022). "Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders". Journal of Neurology. 269 (4): 1786–1801. doi:10.1007/s00415-021-10783-4.
- ↑ MedlinePlus (2026-01-27). "Neuromyelitis optica spectrum disorder". MedlinePlus Medical Encyclopedia. Retrieved 2026-10-31.
- ↑ Lee HL, Kang M, Seok JM, Kim BJ, Kim BJ (2025). "Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis optica spectrum disorders: a population-based cohort study". Therapeutic Advances in Neurological Disorders. 18: 17562864251314020. doi:10.1177/17562864251314020.
- ↑ Qin C, Tian DS, Zhou LQ, et al. (2023). "Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results". Signal Transduction and Targeted Therapy. 8: 5. doi:10.1038/s41392-022-01278-3.